BioSpace - Antigen-Bound and Free ß-Amyloid Autoantibodies in Serum of Healthy Adults

Biotech and Pharmaceutical
News & Jobs

Search the Site

Employers
Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

PLoS By Category | Recent PLoS Articles

Biochemistry - Chemistry - Immunology - Neurological Disorders - Neuroscience

Antigen-Bound and Free ß-Amyloid Autoantibodies in Serum of Healthy Adults
Published: Tuesday, September 04, 2012
Author: Madalina Maftei et al.

by Madalina Maftei, Franka Thurm, Vera Maria Leirer, Christine A. F. von Arnim, Thomas Elbert, Michael Przybylski, Iris-Tatjana Kolassa, Marilena Manea

Physiological ß-amyloid autoantibodies (Aß-autoantibodies) are currently investigated as potential diagnostic and therapeutic tools for Alzheimer’s disease (AD). In previous studies, their determination in serum and cerebrospinal fluid (CSF) using indirect ELISA has provided controversial results, which may be due to the presence of preformed Aß antigen-antibody immune complexes. Based on the epitope specificity of the Aß-autoantibodies, recently elucidated in our laboratory, we developed (a) a sandwich ELISA for the determination of circulating Aß-IgG immune complexes and (b) an indirect ELISA for the determination of free Aß-autoantibodies. This methodology was applied to the analysis of serum samples from healthy individuals within the age range of 18 to 89 years. Neuropsychological examination of the participants in this study indicated non-pathological, age-related cognitive decline, revealed especially by tests of visual memory and executive function, as well as speed-related tasks. The ELISA serum determinations showed significantly higher levels of Aß-IgG immune complexes compared to free Aß-autoantibodies, while no correlation with age or cognitive performance of the participants was found. More...